View Author
patient cancer group study breast chemotherapy control breast cancer treatment peptide sample protein performance adjuvant netherland brain effect number difference score impairment volume response tumor table idh 1 mutations therapy matter bc patients result breast cancer patients tamoxifen maldi-tof memory protein concentration trial control group proteomic masse range mutation exemestane neuropsychological reference netherlands cancer institute cognitively measurement month analysis peak positions astrocytoma survivor research test scores erasmus mc matter volume position method department oncol symptom center participant concentration breast cancer survivors tp 53 mutations identification postmenopausal breast cancer res domain function temozolomide signi women group i subject disease dutch erasmu promoter
9 Most Recent Publications
|
Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy
(Article)
Koppelmans, V. Ruiter, M.B. de Lijn, F. van der Boogerd, W. Seynaeve, C.M. Lugt, A. van der Vrooman, H.A. Niessen, W.J. Breteler, M.M.B. Schagen, S.B. |
2011-12-28
|
|
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: Molecular characteristics in relation to response
(Article)
Taal, W. Dubbink, H.J. Heuvel, I. van Holt, B. van der Bromberg, J.E.C. Smitt, P.A. Dinjens, W.N.M. Bent, M.J. van den Zonnenberg, B.A. Postma, T.J. Gijtenbeek, J. Boogerd, W. Groenendijk, F.H. Kros, J.M. Kouwenhoven, M.C.M. Marion, R. van |
2011-02-01
|
|
Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors
(Article)
Schilder, C.M. Seynaeve, C.M. Linn, S.C. Boogerd, W. Beex, L.V. Gundy, C.M. Nortier, J.W. Velde, C.J.H. van de Dam, F.S. van Schagen, S.B. |
2010-11-01
|
|
The impact of different definitions and reference groups on the prevalence of cognitive impairment: A study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy
(Article)
Schilder, C.M. Seynaeve, C.M. Linn, S.C. Boogerd, W. Gundy, C.M. Beex, L.V. Dam, F.S. van Schagen, S.B. |
2010-04-01
|
|
Increased risk of stroke and transient ischemic attack in 5-year survivors of hodgkin lymphoma
(Article)
Bruin, M.L. de Dorresteijn, L.D.A. Veer, M.B. van 't Krol, A.D.G. Pal, H.J. van der Kappelle, A.C. Boogerd, W. Aleman, B.M.P. Leeuwen, F.E. van |
2009-07-01
|
|
Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study
(Article)
Schilder, C.M. Eggens, P.C. Seynaeve, C.M. Linn, S.C. Boogerd, W. Gundy, C.M. Beex, L.V. Dam, F.S. van Schagen, S.B. |
2009-01-01
|
|
Identification of leptomeningeal metastasis-related proteins in cerebrospinal fluid of patients with breast cancer by a combination of MALDI-TOF, MALDI-FTICR and nanoLC-FTICR MS
(Article)
Römpp, A. Dekker, L.J.M. Taban, I. Jenster, G.W. Boogerd, W. Bonfrer, H. Spengler, B. Heeren, R.M. Smitt, P.S. Luider, T.M. |
2007-02-01
|
|
MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer.
(Article)
Dekker, L.J.M. Boogerd, W. Luider, T.M. Smitt, P.A. Stockhammer, G. Dalebout, J.C. Siccama, I. Zheng, P.P. Bonfrer, J.M. Verschuuren, J.J. Jenster, G.W. Verbeek, M.M. |
2005-09-01
|
|
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
(Article)
Bent, M.J. van den Chinot, O. Boogerd, W. Bravo Marques, J. Taphoorn, M.J. Kros, J.M. Rijt, C.C.D. van der Vecht, C.J. Beule, N. de Baron, B. |
2003-01-01
|
